Analysis compares semaglutide’s cardiovascular benefits with tirzepatide’s weight loss in obesity management, highlighting treatment implications.
Semaglutide and tirzepatide represent foundational options in contemporary obesity pharmacotherapy. Semaglutide offers robust cardiovascular protection; tirzepatide yields greater weight loss and broad metabolic benefits. Both agents require clinicians to reconceptualize obesity as a chronic disease needing ongoing pharmacological management.
No takes yet. Share an insight, caveat, or question.
Mondoh et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: